[go: up one dir, main page]

MX2013006014A - Peptidos tomm34 y vacunas que los incluyen. - Google Patents

Peptidos tomm34 y vacunas que los incluyen.

Info

Publication number
MX2013006014A
MX2013006014A MX2013006014A MX2013006014A MX2013006014A MX 2013006014 A MX2013006014 A MX 2013006014A MX 2013006014 A MX2013006014 A MX 2013006014A MX 2013006014 A MX2013006014 A MX 2013006014A MX 2013006014 A MX2013006014 A MX 2013006014A
Authority
MX
Mexico
Prior art keywords
peptides
peptidos
tomm34
vaccines
amino acid
Prior art date
Application number
MX2013006014A
Other languages
English (en)
Other versions
MX344586B (es
Inventor
Yusuke Nakamura
Takuya Tsunoda
Sachiko Yoshimura
Tomohisa Watanabe
Ryuji Osawa
Gaku Nakayama
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2013006014A publication Critical patent/MX2013006014A/es
Publication of MX344586B publication Critical patent/MX344586B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona péptidos aislados o fragmentos derivados de SEQ ID NO: 42, que enlazan a un antígeno HLA e inducen linfocitos T citotóxicos (CTL). Los péptidos pueden incluir una de las secuencias de aminoácidos anteriormente mencionadas con la sustitución, eliminación, inserción, o adición de uno, dos, o varias secuencias de aminoácido. La presente invención también proporciona composiciones farmacéuticas y métodos para tratar el cáncer que incluyen tales péptidos. Los péptidos de esta invención pueden usarse para tratar cáncer.
MX2013006014A 2010-12-02 2011-11-25 Peptidos tomm34 y vacunas que los incluyen. MX344586B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41918110P 2010-12-02 2010-12-02
PCT/JP2011/006551 WO2012073459A1 (en) 2010-12-02 2011-11-25 Tomm34 peptides and vaccines including the same

Publications (2)

Publication Number Publication Date
MX2013006014A true MX2013006014A (es) 2013-07-29
MX344586B MX344586B (es) 2016-12-20

Family

ID=46171433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006014A MX344586B (es) 2010-12-02 2011-11-25 Peptidos tomm34 y vacunas que los incluyen.

Country Status (23)

Country Link
US (3) US9125849B2 (es)
EP (1) EP2646546B1 (es)
JP (2) JP6064186B2 (es)
KR (1) KR102004900B1 (es)
CN (2) CN103339253B (es)
AR (1) AR084095A1 (es)
AU (1) AU2011336019B2 (es)
BR (1) BR112013013158B1 (es)
CA (1) CA2819463C (es)
CO (1) CO6862100A2 (es)
DK (1) DK2646546T3 (es)
EA (1) EA028216B1 (es)
ES (1) ES2677118T3 (es)
IL (1) IL226068B (es)
MX (1) MX344586B (es)
MY (1) MY166516A (es)
NZ (1) NZ611361A (es)
PH (1) PH12013501105A1 (es)
SG (2) SG190407A1 (es)
TW (1) TWI618541B (es)
UA (1) UA110119C2 (es)
WO (1) WO2012073459A1 (es)
ZA (1) ZA201303886B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6283861B2 (ja) 2012-09-11 2018-02-28 オンコセラピー・サイエンス株式会社 Ｕｂｅ２ｔペプチドおよびそれを含むワクチン
JP2015228191A (ja) * 2014-06-03 2015-12-17 カシオ計算機株式会社 コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末
WO2017150084A1 (ja) * 2016-02-29 2017-09-08 京セラドキュメントソリューションズ株式会社 電子機器およびマーカー処理方法
AU2018213890B2 (en) 2017-01-25 2023-07-20 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
EP0628570A1 (en) 1989-02-17 1994-12-14 Chiron Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
PL311036A1 (en) * 1993-03-19 1996-01-22 Boehringer Ingelheim Int Method of obtaining an anticarcinogenic vaccine
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO2001049310A1 (en) 2000-01-03 2001-07-12 Argonex Pharmaceuticals, Inc. C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
KR101077177B1 (ko) * 2002-06-06 2011-10-27 온코세라피 사이언스 가부시키가이샤 사람 결장암에 관계하는 유전자 및 폴리펩티드
WO2004018667A1 (ja) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
CN103951745A (zh) 2002-09-12 2014-07-30 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
ES2309485T3 (es) 2003-01-06 2008-12-16 Wyeth Composiciones y procedimientos para diagnosticar y tratar los canceres de colon.
ES2456666T3 (es) * 2003-04-18 2014-04-23 Biotech Synergy, Inc. Péptidos antígenos HLA-A2 asociados a un tumor y composiciones
PL1910839T3 (pl) 2005-07-27 2016-11-30 Gen TOM34 związany z nowotworem okrężnicy
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
RU2733985C2 (ru) * 2009-03-18 2020-10-09 Онкотерапи Сайенс, Инк. Пептиды neil3 и включающие их вакцины

Also Published As

Publication number Publication date
CO6862100A2 (es) 2014-02-10
KR102004900B1 (ko) 2019-07-29
SG190407A1 (en) 2013-06-28
ES2677118T3 (es) 2018-07-30
DK2646546T3 (en) 2018-08-06
EP2646546B1 (en) 2018-05-16
BR112013013158A2 (pt) 2017-08-01
CN105111281A (zh) 2015-12-02
MX344586B (es) 2016-12-20
AR084095A1 (es) 2013-04-17
NZ611361A (en) 2014-10-31
US9125849B2 (en) 2015-09-08
US9585948B2 (en) 2017-03-07
CN103339253B (zh) 2015-09-09
IL226068A0 (en) 2013-06-27
SG10201509823WA (en) 2015-12-30
EA028216B1 (ru) 2017-10-31
JP6064186B2 (ja) 2017-01-25
ZA201303886B (en) 2014-03-26
AU2011336019B2 (en) 2016-07-07
CA2819463A1 (en) 2012-06-07
JP2014506114A (ja) 2014-03-13
TW201225973A (en) 2012-07-01
IL226068B (en) 2019-01-31
KR20130121910A (ko) 2013-11-06
EP2646546A4 (en) 2015-12-23
US20170198010A1 (en) 2017-07-13
MY166516A (en) 2018-07-05
CA2819463C (en) 2018-10-23
EA201390811A1 (ru) 2013-12-30
EP2646546A1 (en) 2013-10-09
JP2016222676A (ja) 2016-12-28
US20140023671A1 (en) 2014-01-23
CN103339253A (zh) 2013-10-02
TWI618541B (zh) 2018-03-21
AU2011336019A1 (en) 2013-07-04
US20150374810A1 (en) 2015-12-31
BR112013013158B1 (pt) 2020-04-28
PH12013501105A1 (en) 2013-08-05
UA110119C2 (xx) 2015-11-25
WO2012073459A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
AR087715A1 (es) Anticuerpos anti pcsk9 y usos de los mismos
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX375994B (es) Composicion farmaceutica que comprende particulas de plga-peg.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
MX2015012012A (es) Peptidos de kntc2 y vacunas que los contienen.
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
MX2013006014A (es) Peptidos tomm34 y vacunas que los incluyen.
BR112015010625A2 (pt) Peptídeos
EP3208334A3 (en) Cdc45l peptides and vaccines including the same
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
GB201114923D0 (en) Immunogenic proteins and compositions
TH158366A (th) Topk เปปไทด์ และวัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
FG Grant or registration